Table 3 Baseline characteristics, comorbidities and treatment parameters of different multidrug-resistant Pseudomonas aeruginosa
Parameter | MBL (n = 18) | Non-MBL (n = 95) | P-value | 3/4MDR (n = 27) | Non-3/4MDR (n = 86) | P-value |
|---|---|---|---|---|---|---|
Basic parameters | ||||||
Age, years* | 60 (53-64) | 67 (52-74) | 0.16 | 59 (48-64) | 68.5 (54-75) | 0.01 |
Male sex (%) | 11 (61) | 60 (63) | 0.87 | 17 (63) | 54 (63) | 0.99 |
Fatal outcome (%) | 11 (61) | 32 (34) | 0.03 | 17 (63) | 26 (30) | 0.002 |
Length of stay, days* | 23 (20-45) | 15 (8-41) | 0.03 | 23 (13-45) | 14.5 (7-41) | 0.03 |
Comorbid conditions | ||||||
Immune suppression (%) | 18 (100) | 76 (80) | 0.04 | 27 (100) | 67 (78) | 0.006 |
Neutropenia (%) | 15 (83) | 23 (24) | <0.001 | 17 (63) | 21 (24) | <0.001 |
Cardiovascular disease (%) | 7 (39) | 59 (62) | 0.07 | 11 (41) | 55 (64) | 0.03 |
Diabetes (%) | 5 (28) | 32 (34) | 0.62 | 7 (26) | 30 (35) | 0.39 |
Pulmonary disease (%) | 1 (6) | 10 (11) | 1 | 1 (4) | 10 (12) | 0.46 |
Neurological disease (%) | 2 (11) | 22 (23) | 0.35 | 6 (22) | 18 (21) | 0.89 |
Renal disease (%) | 0 (0) | 11 (12) | 0.21 | 1 (4) | 10 (12) | 0.46 |
Haematological cancer (%) | 17 (94) | 19 (20) | <0.001 | 20 (74) | 16 (19) | <0.001 |
Charlson Comorbidity Score* | 2 (2-3) | 3 (1-5) | 0.86 | 2 (2-3) | 3 (2-5) | 0.27 |
Patients clinical record | ||||||
SAPS II* | 39.5 (36-44) | 32 (23-41) | 0.002 | 37 (28-43) | 32 (24-41) | 0.57 |
AET (%) | 8 (44) | 66 (70) | 0.04 | 11 (41) | 63 (73) | 0.002 |
ADT (%) | 13 (72) | 83 (87) | 0.14 | 19 (70) | 77 (90) | 0.03 |